Phase III trial evaluated subcutaneous abatacept + standard of care (SOC) for idiopathic inflammatory myopathy Over 24 wks, abatacept+SOC failed to show improved efficacy over placebo; however, patients with non-DM subtypes appeared to have sustained benefit up to 1 year A&R acr.tw/3ARxyMs #Medsky

You can now order charity Christmas cards from Myositis UK. This year we have 8 lovely designs to choose from 🌲 By ordering Christmas cards from Myositis UK, you will help us raise vital funds to continue our fighting muscle disease. Thank you for your continued support.